Total Payments
$205,580
2024 Payments
$26,131
Companies
15
Transactions
222
Medicare Patients
56
Medicare Billing
$5,214
Payment Breakdown by Category
Other$90,529 (44.0%)
Consulting$89,014 (43.3%)
Travel$21,551 (10.5%)
Food & Beverage$4,329 (2.1%)
Education$156.82 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Honoraria | $90,505 | 31 | 44.0% |
| Consulting Fee | $89,014 | 49 | 43.3% |
| Travel and Lodging | $21,551 | 77 | 10.5% |
| Food and Beverage | $4,329 | 59 | 2.1% |
| Education | $156.82 | 5 | 0.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $24.00 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Blueprint Medicines Corporation | $120,601 | 129 | $0 (2024) |
| AstraZeneca UK Limited | $51,433 | 30 | $0 (2024) |
| Pharming Healthcare, Inc. | $6,745 | 9 | $0 (2020) |
| CSL Behring | $6,598 | 10 | $0 (2020) |
| Shire North American Group Inc | $4,812 | 3 | $0 (2019) |
| GlaxoSmithKline, LLC. | $3,376 | 13 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $3,052 | 8 | $0 (2023) |
| BioCryst Pharmaceuticals, Inc. | $2,434 | 6 | $0 (2019) |
| Phadia US Inc. | $2,000 | 3 | $0 (2017) |
| Genentech, Inc. | $1,607 | 3 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $26,131 | 21 | Blueprint Medicines Corporation ($13,578) |
| 2023 | $97,348 | 110 | Blueprint Medicines Corporation ($82,046) |
| 2022 | $39,149 | 28 | Blueprint Medicines Corporation ($19,531) |
| 2021 | $7,400 | 4 | AstraZeneca UK Limited ($7,400) |
| 2020 | $12,239 | 9 | Blueprint Medicines Corporation ($5,445) |
| 2019 | $13,560 | 24 | Shire North American Group Inc ($4,699) |
| 2018 | $2,799 | 15 | Genentech, Inc. ($1,607) |
| 2017 | $6,955 | 11 | CSL Behring ($4,661) |
All Payment Transactions
222 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | AstraZeneca UK Limited | FASENRA (Biological) | Consulting Fee | Cash or cash equivalent | $1,800.00 | General |
| Category: Respiratory | ||||||
| 10/24/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Food and Beverage | In-kind items and services | $132.40 | General |
| Category: Oncology / Rare Diseases | ||||||
| 10/16/2024 | AstraZeneca UK Limited | FASENRA (Biological) | Consulting Fee | Cash or cash equivalent | $1,600.00 | General |
| Category: Respiratory | ||||||
| 10/15/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $99.19 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 10/09/2024 | AstraZeneca UK Limited | FASENRA (Biological) | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| Category: Respiratory | ||||||
| 10/06/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Consulting Fee | Cash or cash equivalent | $763.20 | General |
| Category: Oncology / Rare Diseases | ||||||
| 08/28/2024 | AstraZeneca UK Limited | FASENRA (Biological) | Consulting Fee | Cash or cash equivalent | $1,400.00 | General |
| Category: Respiratory | ||||||
| 08/25/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Consulting Fee | Cash or cash equivalent | $763.20 | General |
| Category: Oncology / Rare Diseases | ||||||
| 07/31/2024 | AstraZeneca UK Limited | FASENRA (Biological) | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| Category: Respiratory | ||||||
| 06/14/2024 | AstraZeneca UK Limited | FASENRA (Biological) | Consulting Fee | Cash or cash equivalent | $2,900.00 | General |
| Category: Respiratory | ||||||
| 05/12/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Consulting Fee | Cash or cash equivalent | $1,144.80 | General |
| Category: Oncology / Rare Diseases | ||||||
| 05/05/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Consulting Fee | Cash or cash equivalent | $954.00 | General |
| Category: Oncology / Rare Diseases | ||||||
| 04/28/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Consulting Fee | Cash or cash equivalent | $7,822.80 | General |
| Category: Oncology / Rare Diseases | ||||||
| 04/28/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Consulting Fee | Cash or cash equivalent | $1,224.68 | General |
| Category: Oncology / Rare Diseases | ||||||
| 04/28/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Consulting Fee | Cash or cash equivalent | $60.50 | General |
| Category: Oncology / Rare Diseases | ||||||
| 04/14/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Consulting Fee | Cash or cash equivalent | $572.40 | General |
| Category: Oncology / Rare Diseases | ||||||
| 02/25/2024 | TerSera Therapeutics LLC | Quzyttir (Drug) | Consulting Fee | Cash or cash equivalent | $860.00 | General |
| Category: Acute Care | ||||||
| 02/25/2024 | TerSera Therapeutics LLC | Quzyttir (Drug) | Food and Beverage | In-kind items and services | $93.49 | General |
| Category: Acute Care | ||||||
| 02/24/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Food and Beverage | In-kind items and services | $90.49 | General |
| Category: Oncology / Rare Diseases | ||||||
| 02/23/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Food and Beverage | In-kind items and services | $49.90 | General |
| Category: Oncology / Rare Diseases | ||||||
| 02/14/2024 | AstraZeneca UK Limited | FASENRA (Biological) | Consulting Fee | Cash or cash equivalent | $1,400.00 | General |
| Category: Respiratory | ||||||
| 12/28/2023 | AstraZeneca UK Limited | FASENRA (Biological) | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| Category: Respiratory | ||||||
| 12/03/2023 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Consulting Fee | Cash or cash equivalent | $1,526.40 | General |
| Category: Oncology / Rare Diseases | ||||||
| 12/03/2023 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Consulting Fee | Cash or cash equivalent | $763.20 | General |
| Category: Oncology / Rare Diseases | ||||||
| 11/19/2023 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Consulting Fee | Cash or cash equivalent | $3,052.80 | General |
| Category: Oncology / Rare Diseases | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 1 | 25 | 31 | $9,207 | $2,142 |
| 2020 | 2 | 31 | 55 | $16,435 | $3,072 |
Total Patients
56
Total Services
86
Medicare Billing
$5,214
Procedure Codes
3
All Medicare Procedures & Services
3 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 25 | 31 | $9,207 | $2,142 | 23.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 19 | 39 | $11,349 | $2,041 | 18.0% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 12 | 16 | $5,086 | $1,031 | 20.3% |
About Dr. Lawrence Schwartz, M.D
Dr. Lawrence Schwartz, M.D is a Internal Medicine healthcare provider based in Richmond, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/12/2006. The National Provider Identifier (NPI) number assigned to this provider is 1508955659.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Lawrence Schwartz, M.D has received a total of $205,580 in payments from pharmaceutical and medical device companies, with $26,131 received in 2024. These payments were reported across 222 transactions from 15 companies. The most common payment nature is "Honoraria" ($90,505).
As a Medicare-enrolled provider, Schwartz has provided services to 56 Medicare beneficiaries, totaling 86 services with total Medicare billing of $5,214. Data is available for 2 years (2020–2021), covering 3 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Rheumatology
- Location Richmond, VA
- Active Since 10/12/2006
- Last Updated 09/11/2025
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1508955659
Products in Payments
- AYVAKIT (Drug) $100,661
- FASENRA (Biological) $49,518
- RUCONEST (Biological) $6,745
- Haegarda (Biological) $6,598
- TAKHZYRO (Biological) $4,699
- TEZSPIRE (Biological) $2,400
- FASENRA (Drug) $2,113
- ImmunoCAP (Device) $2,000
- Non-Covered Product (Drug) $1,607
- Quzyttir (Drug) $953.49
- DUPIXENT (Biological) $358.73
- NUCALA (Biological) $202.88
- DUPIXENT (Drug) $76.81
- PALFORZIA (Biological) $33.72
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Richmond
Dr. George Vetrovec, M.d, M.D
Internal Medicine — Payments: $3.2M
Internal Medicine $3.2M
Dr. Arun Sanyal, M.d, M.D
Internal Medicine — Payments: $956,666
Internal Medicine $956,666
Dr. Erica Gregonis, Md, MD
Internal Medicine — Payments: $314,689
Internal Medicine $314,689
Dr. Wally Smith, M.d, M.D
Internal Medicine — Payments: $195,657
Internal Medicine $195,657
Dr. Gaurav Gupta, Md, MD
Internal Medicine — Payments: $189,406
Internal Medicine $189,406
Dr. Andrew Poklepovic, M.d, M.D
Internal Medicine — Payments: $112,763
Internal Medicine $112,763